TGF-ß in Immunity, Inflammation and Cancer
Organizer(s): Wanjun Chen, Joanne E. Konkel and Richard A. FlavellDate: January 09 - 13, 2017
Location: Sagebrush Inn & Suites, Taos, NM, USA
TGF-beta is a key regulator of immune responses, inflammation and cancer. In addition to the well-established effects of TGF-beta on CD4+ T cell differentiation and reprogramming, TGF-beta also plays critical roles in other immune cells. Furthermore, TGF-beta has been implicated in the regulation of the interactions among immune cells, microbiota and epithelial cells. In addition to safeguarding immune homeostasis and suppressing chronic inflammation and autoimmunity, TGF-beta is emerging as a potential checkpoint in anti-tumor immunity. Despite great progress in the field, key questions related to TGF-beta functions in immune responses are still largely undetermined. Therefore, it is imperative to understand the cellular and molecular mechanisms by which TGF-beta controls such diverse immune cells. Elucidation of these pathways would allow us to understand the pathogenesis of chronic inflammation, autoimmunity and cancer and aid development of therapeutic practices in experimental and ultimately clinical settings. This meeting will gather together experts in the fields of both TGF-beta signaling and immunology to discuss new findings and update the pivotal role of TGF-beta in immunity, inflammation and cancer, with the aim to lay out the critical and key questions and outline new directions.
Scholarship Deadline: September 20 2016
Discounted Abstract Deadline: September 20 2016
Abstract Deadline: October 11 2016
Discounted Registration Deadline: November 10 2016
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Eli Lilly and Company
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI126781-01
Funding for this conference was made possible (in part) by 1R13AI126781-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.